Please login to the form below

Not currently logged in


This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

NICE gives nod to Gilead’s Zydelig

NICE gives nod to Gilead’s Zydelig

Zydelig (idelalisib) has been indicated in final draft guidance for patients whose leukaemia has come back less than 24 months after previous treatment. ... had agreed to provide idelalisib to the NHS at a reduced price in the initial submission. “

Latest news

More from news
Approximately 2 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Gower Publishing Limited

Gower is recognised as one of the world's leading publishers of specialist business and management books and resources. Our publishing...

Latest intelligence

White paper download: Creating experiences to improve patient outcomes
Download our white paper "Creating experiences to improve patient outcomes" to learn the steps to building an effective customer experience strategy....
Organisational Memory
In a knowledge-based industry with high labour mobility, retaining that knowledge within an organisation during a drug’s lifecycle can be tricky. If we undervalue the knowledge, experience and marketing understanding...
Thoughts on the intersection between technology and psychology
Paul Mannu - Master Practitioner, Behavioural Insights at Cello Health Insight gives us his succinct thoughts on the intersection between technology and psychology...